Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CPB1 | P15086 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL757461 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL2374934 | 0.86 | PKM (0.52) | ALDH1A1MAPTNPSR1 | |
| SCHEMBL2374933 | 0.86 | PKM (0.52) | ALDH1A1MAPTNPSR1 | |
| SCHEMBL25877951 | 0.85 | ALDH1A1 (0.45) | ALDH1A1CTSLCTSBCTSKGAA | |
| SCHEMBL22849511 | 0.85 | ALDH1A1 (0.55) | ALDH1A1CTSLCTSBCTSKGAA | |
| SCHEMBL3398972 | 0.85 | ALDH1A1 (0.55) | ALDH1A1CTSLCTSBCTSKGAA | |
| SCHEMBL24373187 | 0.84 | AGTR2 (0.41) | ALDH1A1GAA | |
| SCHEMBL28840618 | 0.84 | ALDH1A1 (0.43) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL15012790 | 0.83 | ALDH1A1 (0.45) | ALDH1A1MAPTHPGDNPSR1HSD17B10 | |
| SCHEMBL15012791 | 0.83 | ALDH1A1 (0.45) | ALDH1A1MAPTHPGDNPSR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857535-B2 | Methods of treating mutant lymphomas | KYMERA THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857535-B2 | Methods of treating mutant lymphomas | KYMERA THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-11707457-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2023283610-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023283372-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-20120208816-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-8193349-B2 | 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193349-B2 | 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| EP-2404901-A1 | 1,2-Disubstituted 4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis | Novartis AG (CH) | 2012-01-11 | — | — | EP | disclosed |
| EP-2229356-B1 | 1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2011-10-12 | — | — | EP | disclosed |
| US-20100311750-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
| US-20100311750-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
| WO-2009059943-A1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2009-05-14 | — | — | WO | disclosed |
| US-20090118287-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
| US-20090118287-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11857535-B2 | Methods of treating mutant lymphomas | IRAK4, IRAK2, IRAK3 | ALDH1A1 2878/4885MAPT 3618/4885HPGD 4596/4885 |
| US-20090118287-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | ALDH1A1 1701/4885MAPT 1522/4885HPGD 3425/4885 |
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885MAPT 2459/4885HPGD 3843/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885MAPT 2459/4885HPGD 3843/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885MAPT 2459/4885HPGD 3843/4885 |
| US-20120208816-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | ALDH1A1 1701/4885MAPT 1522/4885HPGD 3425/4885 |
| US-20100311750-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | ALDH1A1 1789/4885MAPT 1488/4885HPGD 3694/4885 |
| US-11707457-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885MAPT 2459/4885HPGD 3843/4885 |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885MAPT 2459/4885HPGD 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.